Sera Prognostics (NASDAQ:SERA) and Basel Medical Group (NASDAQ:BMGL) Head to Head Survey

Basel Medical Group (NASDAQ:BMGL) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Profitability

This table compares Basel Medical Group and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Sera Prognostics	-39,417.29%	-37.50%	-29.02%

Insider and Institutional Ownership

54.6% of Sera Prognostics shares are held by institutional investors. 15.8% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Basel Medical Group and Sera Prognostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90 million	1.25	-$9.50 million	N/A	N/A
Sera Prognostics	$80,000.00	1,032.81	-$31.93 million	($0.68)	-3.10

Basel Medical Group has higher revenue and earnings than Sera Prognostics.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Basel Medical Group and Sera Prognostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1	0	0	0	1.00
Sera Prognostics	1	0	0	1	2.50

Sera Prognostics has a consensus target price of $5.00, indicating a potential upside of 136.85%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Basel Medical Group.

Summary

Sera Prognostics beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

About Basel Medical Group

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.